MCID: LNG072
MIFTS: 31

Lung Cancer Susceptibility 2

Categories: Genetic diseases, Respiratory diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Lung Cancer Susceptibility 2

MalaCards integrated aliases for Lung Cancer Susceptibility 2:

Name: Lung Cancer Susceptibility 2 54 13 69
Nicotine Dependence 54 69
Smoking As a Quantitative Trait Locus 3 29

Classifications:



External Ids:

OMIM 54 612052

Summaries for Lung Cancer Susceptibility 2

MalaCards based summary : Lung Cancer Susceptibility 2, also known as nicotine dependence, is related to nicotine dependence, protection against and schizophrenia. An important gene associated with Lung Cancer Susceptibility 2 is CHRNA5 (Cholinergic Receptor Nicotinic Alpha 5 Subunit), and among its related pathways/superpathways are Transmission across Chemical Synapses and Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics. The drugs Betamethasone and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include lung and neutrophil, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Description from OMIM: 612052

Related Diseases for Lung Cancer Susceptibility 2

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 2:



Diseases related to Lung Cancer Susceptibility 2

Symptoms & Phenotypes for Lung Cancer Susceptibility 2

Clinical features from OMIM:

612052

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 2 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.23 CHRNA3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.23 CHRNA3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.23 CHRNA5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.23 CHRNA5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.23 CHRNA5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.23 CHRNA3 CHRNA5
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.23 CHRNA5

Drugs & Therapeutics for Lung Cancer Susceptibility 2

Drugs for Lung Cancer Susceptibility 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 2 378-44-9 9782
2
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
3
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
4
Simvastatin Approved Phase 2 79902-63-9 54454
5 Anti-Asthmatic Agents Phase 2
6 Anti-Inflammatory Agents Phase 2
7 Betamethasone benzoate Phase 2
8 Betamethasone sodium phosphate Phase 2
9 Betamethasone Valerate Phase 2 2152-44-5
10 Betamethasone-17,21-dipropionate Phase 2
11
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
12 glucocorticoids Phase 2
13 Hormone Antagonists Phase 2
14 Hormones Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
16 Mitogens Phase 2
17 Respiratory System Agents Phase 2
18 Anticholesteremic Agents Phase 2
19 Antimetabolites Phase 2
20 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
21 Hypolipidemic Agents Phase 2
22 Lipid Regulating Agents Phase 2
23 Protein Kinase Inhibitors Phase 2
24
Menthol Approved 2216-51-5 16666
25
B-Carotene Approved, Nutraceutical 7235-40-7 5280489
26 Tocopherol Approved, Nutraceutical
27
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985
28 Gastrointestinal Agents
29 glucagon
30 Glucagon-Like Peptide 1
31 Incretins
32 Antioxidants
33 Carotenoids
34 Micronutrients
35 Protective Agents
36 Tocopherols
37 Tocotrienols
38 Trace Elements
39 Vitamins
40 Tocotrienol Investigational, Nutraceutical 6829-55-6
41 Cola Nutraceutical

Interventional clinical trials:

(show all 19)

id Name Status NCT ID Phase Drugs
1 Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors Completed NCT00910676 Phase 2 Diprosone
2 Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC) Completed NCT00452244 Phase 2 simvastatin;gefitinib only
3 Immunotherapy by Nivolumab for HIV+ Patients Not yet recruiting NCT03304093 Phase 2 Nivolumab Injection
4 Visualising c-MET and Activated Neutrophils in Lung Cancer Not yet recruiting NCT02676050 Phase 1
5 The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism Unknown status NCT01280448
6 Genetic Epidemiological Study of Lung Cancer in Taiwan and Clinical Applications Unknown status NCT00260871
7 The Roles of Neutrophil Elastase in Lung Cancer Unknown status NCT01360931
8 Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy Completed NCT01382667
9 Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation Completed NCT01580579
10 Blood Collection From Individuals With Lung Disease for Genetic Studies Completed NCT00362739
11 Preoperative High Intensity Interval Training: The PHIIT Trial Completed NCT02674815
12 Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2 Completed NCT02284295
13 Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Completed NCT00342992
14 Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Recruiting NCT00579514
15 Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome Recruiting NCT00406445
16 International Ovarian & Testicular Stromal Tumor Registry Recruiting NCT01970696
17 Genetic Susceptibility to Lung Cancer in Never Smokers Active, not recruiting NCT00597636
18 DNA Repair and Genetic Susceptibility to Lung Cancer Active, not recruiting NCT00611598
19 Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer Active, not recruiting NCT01982149

Search NIH Clinical Center for Lung Cancer Susceptibility 2

Genetic Tests for Lung Cancer Susceptibility 2

Genetic tests related to Lung Cancer Susceptibility 2:

id Genetic test Affiliating Genes
1 Smoking As a Quantitative Trait Locus 3 29

Anatomical Context for Lung Cancer Susceptibility 2

MalaCards organs/tissues related to Lung Cancer Susceptibility 2:

39
Lung, Neutrophil

Publications for Lung Cancer Susceptibility 2

Variations for Lung Cancer Susceptibility 2

ClinVar genetic disease variations for Lung Cancer Susceptibility 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CHRNA5 NM_000745.3(CHRNA5): c.1192G> A (p.Asp398Asn) single nucleotide variant risk factor rs16969968 GRCh37 Chromosome 15, 78882925: 78882925
2 CHRNA3 NM_001166694.1(CHRNA3): c.645C> T (p.Tyr215=) single nucleotide variant drug response rs1051730 GRCh37 Chromosome 15, 78894339: 78894339

Expression for Lung Cancer Susceptibility 2

Search GEO for disease gene expression data for Lung Cancer Susceptibility 2.

Pathways for Lung Cancer Susceptibility 2

Pathways related to Lung Cancer Susceptibility 2 according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.81 CHRNA3 CHRNA5
2
Show member pathways
10.63 CHRNA3 CHRNA5

GO Terms for Lung Cancer Susceptibility 2

Cellular components related to Lung Cancer Susceptibility 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.26 CHRNA3 CHRNA5
2 synapse GO:0045202 9.16 CHRNA3 CHRNA5
3 postsynaptic membrane GO:0045211 8.96 CHRNA3 CHRNA5
4 acetylcholine-gated channel complex GO:0005892 8.62 CHRNA3 CHRNA5

Biological processes related to Lung Cancer Susceptibility 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.32 CHRNA3 CHRNA5
2 ion transmembrane transport GO:0034220 9.26 CHRNA3 CHRNA5
3 excitatory postsynaptic potential GO:0060079 9.16 CHRNA3 CHRNA5
4 synaptic transmission, cholinergic GO:0007271 8.96 CHRNA3 CHRNA5
5 behavioral response to nicotine GO:0035095 8.62 CHRNA3 CHRNA5

Molecular functions related to Lung Cancer Susceptibility 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.32 CHRNA3 CHRNA5
2 ligand-gated ion channel activity GO:0015276 9.26 CHRNA3 CHRNA5
3 acetylcholine binding GO:0042166 9.16 CHRNA3 CHRNA5
4 acetylcholine-gated cation-selective channel activity GO:0022848 8.96 CHRNA3 CHRNA5
5 acetylcholine receptor activity GO:0015464 8.62 CHRNA3 CHRNA5

Sources for Lung Cancer Susceptibility 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....